221 related articles for article (PubMed ID: 7184489)
21. Immunoregulation of antitumor response; differential secretion of arachidonic acid metabolites by macrophages during stimulation in vitro with BCG and Corynebacterium parvum.
Tomecki J; Sukiennik J; Kordowiak A
Arch Immunol Ther Exp (Warsz); 1993; 41(1):45-50. PubMed ID: 8239907
[TBL] [Abstract][Full Text] [Related]
22. Role of inflammatory neutrophils in antitumor effects induced by intraperitoneal administration of Corynebacterium parvum in mice.
Lichtenstein AK; Berek J; Kahle J; Zighelboim J
Cancer Res; 1984 Nov; 44(11):5118-23. PubMed ID: 6488171
[TBL] [Abstract][Full Text] [Related]
23. The effect of Corynebacterium parvum in influenza infected mice.
Białek J; Denys A; Kowalska M; Ciebiada I; Szydłowska T
Arch Immunol Ther Exp (Warsz); 1989; 37(3-4):421-30. PubMed ID: 2639639
[TBL] [Abstract][Full Text] [Related]
24. Lewis lung carcinoma in mice as an experimental therapy model. I. The growth kinetics and the effect of tumor on host.
Budzyński W
Arch Immunol Ther Exp (Warsz); 1982; 30(5-6):363-72. PubMed ID: 7184487
[TBL] [Abstract][Full Text] [Related]
25. [Effect of the age of the mouse on the action of Corynebacterium parvum in inhibiting the growth of 2 syngenetic tumors].
Mazureka C; Stiffel C; Chalvet H; Biozzi G
C R Seances Acad Sci III; 1981 Oct; 293(4):225-8. PubMed ID: 6794870
[TBL] [Abstract][Full Text] [Related]
26. [Passive transfer of "Corynebacterium parvum" anti-tumour protection by stimulated peritoneal cells ].
Mazurek C; Stiffel C; Chalvet H; Biozzi G
Ann Immunol (Paris); 1981; 132D(1):43-54. PubMed ID: 6896973
[TBL] [Abstract][Full Text] [Related]
27. Dose, route, and time dependence of serum lysozyme and antitumor activity following administration of glucan, Corynebacterium parvum, pyran, or lipopolysaccharide to mice.
Gorecka-Tisera A; Proctor JW; Yamamura Y; Harnaha J; Meinert K
J Natl Cancer Inst; 1981 Oct; 67(4):911-5. PubMed ID: 6944557
[TBL] [Abstract][Full Text] [Related]
28. [Effects on the lymphreticular system and inhibition of liver microsomaal cytochrome P-450 in mice administered Priopionibacterium acnes (Corynebacterium parvum) bacterin].
Ocenásková J; Mára M; Bednár M; Veselská M; Adamcová D
Cesk Epidemiol Mikrobiol Imunol; 1985 Mar; 34(2):100-6. PubMed ID: 3157461
[No Abstract] [Full Text] [Related]
29. An experimental screening for "systemic adjuvants of immunity" applicable in cancer immunotherapy.
Mathé G; Kamel M; Dezfulian M; Halle-Pannenko O; Bourut C
Cancer Res; 1973 Sep; 33(9):1987-97. PubMed ID: 4146853
[No Abstract] [Full Text] [Related]
30. Lewis lung carcinoma in mice as an experimental therapy model. II. The effect of BCNU, cyclophosphamide and/or surgery treatment on early and advanced tumor in mice.
Budzyński W
Arch Immunol Ther Exp (Warsz); 1982; 30(5-6):373-7. PubMed ID: 7184488
[TBL] [Abstract][Full Text] [Related]
31. [Antitumor effect of Corynebacterium parvum].
Mazurek C; Chalvet H; Biozzi G; Stiffel C
Ann Immunol (Paris); 1977; 128(1-2):161-3. PubMed ID: 576780
[TBL] [Abstract][Full Text] [Related]
32. Antitumor immunity induced by hybrid murine tumor cells: requirements for optimal immunization.
McCune CS; O'Donnell RW; Horan PK; Budd HS; Spennacchio JL; Chuang C; Henshaw EC
J Natl Cancer Inst; 1982 Sep; 69(3):647-52. PubMed ID: 6955557
[TBL] [Abstract][Full Text] [Related]
33. Active immunization of rats against two tumoral ascites using live cells associated with Corynebacterium parvum.
Lupu A
Arch Roum Pathol Exp Microbiol; 1987; 46(2):167-71. PubMed ID: 3455654
[No Abstract] [Full Text] [Related]
34. Doxorubicin, cisplatin, and Corynebacterium parvum in non-small cell bronchogenic carcinoma.
Drapkin R; Bjornsson S; Naeher C; Higby D; Caracandas J; Wallens WT; Kuberka N; Suh K; Siddiqi N; Henderson ES
Cancer Treat Rep; 1980; 64(12):1367-9. PubMed ID: 7193520
[TBL] [Abstract][Full Text] [Related]
35. Successful immunotherapy with intraperitoneal Corynebacterium parvum in a murine ovarian cancer model is associated with the recruitment of tumor-lytic neutrophils into the peritoneal cavity.
Lichtenstein AK; Kahle J; Berek J; Zighelboim J
J Immunol; 1984 Jul; 133(1):519-26. PubMed ID: 6373934
[TBL] [Abstract][Full Text] [Related]
36. Induction of spleen cell growth and DNA polymerase activity by Corynebacterium parvum.
Maruyama Y; Coleman MS
Cancer Res; 1978 Jun; 38(6):1617-20. PubMed ID: 647675
[TBL] [Abstract][Full Text] [Related]
37. Experience with the quality control testing of C. parvum suspension for clinical trial.
Knight PA; Lucken RN
Dev Biol Stand; 1977 Apr 13-15; 38():51-8. PubMed ID: 608544
[TBL] [Abstract][Full Text] [Related]
38. Effect of immunomodulation on the fate of tumor cells in the central nervous system and systemic organs of mice. Distribution of [125I]5-Iodo-2'-deoxyuridine-labeled KHT tumor cells after left intracardial injection.
Conley FK
J Natl Cancer Inst; 1982 Aug; 69(2):465-73. PubMed ID: 6955547
[TBL] [Abstract][Full Text] [Related]
39. Antitumor activity of Corynebacterium parvum.
Milas L; Scott MT
Adv Cancer Res; 1978; 26():257-306. PubMed ID: 343523
[No Abstract] [Full Text] [Related]
40. Effect of vaccine prepared from Corynebacterium parvum on the growth of Gardner lymphosarcoma in C3H strain mice.
Motycka K; Chudomel V; Bednár M; Bostík J
Arch Immunol Ther Exp (Warsz); 1984; 32(4):405-12. PubMed ID: 6549499
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
